0%
Print report
Variant interpretation report

CTNNB1 c.59C>T, p.Ala20Val

NM_001904.4:c.59C>T NP_001895.1:p.(Ala20Val) Missense · exon 3 View identifiers
Classification
Likely benign

Variant description:

The CTNNB1 NM_001904.4:c.59C>T (NP_001895.1:p.(Ala20Val)) missense variant has previously been reported in somatic cancers (COSMIC; COSV62708242, n = 8 times). Based on available guidelines, this variant is considered to be Likely Benign.

Five-step scale from benign to pathogenic. This variant is likely benign. Select a step to read what it means.

Likely benign.A likely benign classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About CTNNB1

CTNNB1 encodes beta-catenin, a protein with dual roles in cell adhesion and gene regulation. It is part of the adherens junctions that maintain epithelial cell layers by controlling cell growth and cell-cell adhesion, and it also anchors the actin cytoskeleton and helps transmit the signal that stops cells from dividing once a tissue layer is complete. In the WNT signaling pathway, beta-catenin acts as a transcriptional activator that switches on growth-related genes such as Cyclin D1 and MYC. The gene is associated with colorectal cancer, pilomatrixoma, medulloblastoma, and ovarian cancer, and it acts as an oncogene: excessive beta-catenin activity is common in many solid tumors, including uterine, ovarian, liver, and colorectal cancers.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 2
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 all-comers AF is 2.47877e-06 from 4/1,613,702 alleles, below the 0.0001 PM2 cutoff, with zero homozygotes.

Benign criteria applied · 2
BP4Supporting
BP4 · supporting

Met, supporting: REVEL 0.085 is below the <=0.29 BP4 threshold for this missense variant.

BP5Supporting
BP5 · supporting

Met, Supporting: the exact p.A20V colorectal tumor also carried several inactivating APC mutations, an alternate molecular basis for disease.

Recorded classification: Likely benign

Likely Benign: BP4 and BP5, both supporting benign criteria, satisfy the generic ACMG/AMP two-supporting benign rule; PM2 moderate is insufficient for a pathogenic call.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
4 / 1,613,702 alleles

gnomAD v4.1: 4 / 1,613,702 alleles. Recorded AF 2.47877e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.41575e-05; MAF= 0.00142%, 4/282536 alleles, homozygotes = 0) and has highest observed frequency in the European (Finnish) population (AF= 7.96432e-05; MAF= 0.00796%, 2/25112 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.085 recorded score

Recorded REVEL score: 0.085. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
2 reported laboratory submissions

2 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. CTNNB1 (β-catenin), a transcriptional activator, is recurrently mutated in various cancers including endometrial and hepatocellular cancers.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
8 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV62708242, n = 8 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 3 met · 8 not met · 12 not assessed · 5 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

For PS1, PM1, and PM5, the available residue-level observations do not satisfy the required established-pathogenic comparator or validated hotspot/domain conditions at ACMG/AMP 2015 strength.

PP2 and BP1 are not assessed because the supplied, source-registry-citable evidence lacks the required gene-wide missense-mechanism and truncating-spectrum support.

PS2, PM6, PP1, and BS4 are all not_assessed because the available evidence contains no proband-level parental testing, confirmed or assumed de novo germline observation, affected-relative segregation, or affected-relative non-segregation data.

Somatic tumor reports and in-silico analyses of p.(Ala20Val) do not substitute for germline family evidence for these criteria.

No VCEP covers CTNNB1, so generic ACMG/AMP 2015 rules govern.

The variant is missense (p.(Ala20Val)); generic PP3/BP4 therefore use the REVEL path only, not SpliceAI or BayesDel.

REVEL 0.085 is below the PP3 threshold of >=0.644 and meets the BP4 threshold of <=0.29; both criteria are applied only at ACMG/AMP 2015 supporting strength.

Population evidence supports PM2 at Moderate strength based on the gnomAD v4.1 all-comers frequency of 2.47877e-06, while BA1 and BS1 require the unavailable grpmax FAF and BS2 lacks an individual-level healthy-adult observation.

Met · 3

PM2 ModerateACMG_2015Met at Moderate: gnomAD v4.1 all-comers AF is 2.47877e-06 from 4/1,613,702 alleles, below the 0.0001 PM2 cutoff, with zero homozygotes. Details ▾Hide ▴
Reasoning

PM2 is met at the specified ACMG/AMP 2015 Moderate strength. Under the default generic population source, gnomAD v4.1 all-comers reports the variant at AF 2.4787724127503096e-06 (4/1,613,702 alleles) with zero homozygotes, which is below the supplied extremely-low-frequency cutoff of 0.0001. The gnomAD v2.1 all-comers record is concordant at AF 1.415748789534785e-05 (4/282,536 alleles) with zero homozygotes. No VCEP rule requires a non-cancer or exome-only source, so the combined all-comers totals are the governing default.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 all-comers record for CTNNB1 NM_001904.4:c.59C>T: total AF 2.4787724127503096e-06, 4/1,613,702 alleles, homozygotes 0.
  • gnomAD v2.1 all-comers record: total AF 1.415748789534785e-05, 4/282,536 alleles, homozygotes 0.
  • The available non-cancer subsets are not used because no governing VCEP specifies a non-cancer or exome-only source; the generic default is the all-comers GNOMAD_V2_1/GNOMAD_V4_1 entries.
  • The governing generic calibration supplied for PM2 is <= 0.0001, identified as the ACMG/AMP 2015 extremely-low-frequency cutoff (PMID:25741868).
Sources
BP4 SupportingACMGMet, supporting: REVEL 0.085 is below the <=0.29 BP4 threshold for this missense variant. Details ▾Hide ▴
Reasoning

NM_001904.4:c.59C>T, p.(Ala20Val), is a missense variant, so the generic missense path uses REVEL only; SpliceAI and BayesDel are not used for PP3/BP4 in this situation. The REVEL score is 0.085, at or below the BP4 supporting threshold of <= 0.29. Therefore BP4 is met at the ACMG/AMP 2015 supporting strength.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)...BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: NM_001904.4:c.59C>T produces NP_001895.1:p.(Ala20Val), a missense substitution; the generic missense path therefore uses REVEL only.
  • Local REVEL predictor lookup: score 0.085.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): BP4 supporting threshold is <= 0.29; 0.085 meets it.
  • SpliceAI max delta 0.003 and BayesDel -0.403019 were not counted because they are not the named predictor path for a missense variant under the generic rule, and the same prediction must not be double-counted across PP3/BP4/BP7.
Sources
BP5 SupportingACMG_2015Met, Supporting: the exact p.A20V colorectal tumor also carried several inactivating APC mutations, an alternate molecular basis for disease. Details ▾Hide ▴
Reasoning

PMID:21901162 reports the exact CTNNB1 p.A20V variant in a colorectal-cancer tumor and states that the same tumor had several inactivating APC mutations; the authors also state that p.A20V may not be disease-causing. This is a documented case containing an alternate molecular basis for the tumor disease and supports BP5 at the ACMG/AMP 2015 Supporting strength, although the evidence is somatic-cancer context rather than a germline Mendelian case and merits human review.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • PMID:21901162, Results and Discussion: one of 103 colorectal tumors carried p.A20V, and that tumor had several inactivating APC mutations; the authors wrote that p.A20V may not be disease-causing.
  • This supports the BP5 concept of an alternate molecular basis, but the report does not establish germline disease causation for CTNNB1 p.A20V.
Still missing
  • Human review should confirm that the somatic colorectal-cancer context is acceptable for BP5 in this germline interpretation.
Sources

Not met · 8 · evaluated, threshold not reached

PS1 ACMG_2015Not met: p.Ala20Val is classified as uncertain significance in ClinVar, and available tumor reports do not establish a pathogenic germline amino-acid change. Details ▾Hide ▴
Reasoning

The variant is NP_001895.1:p.(Ala20Val), but the available exact-variant reports are somatic tumor observations or computational analyses, not a previously established pathogenic germline amino-acid change. PMID:33535453 calls the tumor finding pathogenic, but the paper-extract evidence states that this was database-based annotation rather than CTNNB1 p.Ala20Val functional or germline clinical evidence; ClinVar classifies the exact variant as uncertain significance. Therefore the requirement for a previously established pathogenic variant with the same amino-acid change is not met.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • ClinVar variation 1346762, exact variant NM_001904.4(CTNNB1):c.59C>T (p.Ala20Val): Uncertain significance, two submitters, no conflicts.
  • Molecular Profiling of Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma, PMID:33535453, Results section 3.5: CTNNB1 c.59C>T; p.(Ala20Val) was observed in a tumor at 9% VAF; the extraction notes that the pathogenic label was database annotation, not variant-specific functional or germline clinical evidence.
Sources
PS3 ACMG_2015Not met: available evidence is computational or tumor-observational, with no validated in vitro or in vivo assay demonstrating a damaging effect for p.Ala20Val. Details ▾Hide ▴
Reasoning

The available variant-specific evidence does not meet PS3. PMID:39202333 reports computational kinase-motif and protein-stability predictions for CTNNB1 c.59C>T (p.Ala20Val), not an in vitro or in vivo functional assay, and explicitly states that functional assays are required for validation. PMID:32365560 provides tumor immunohistochemistry for a differently described CTNNB1 alteration (p.A13V under the paper's numbering) and reports no nuclear beta-catenin accumulation, but it is not a validated assay of this exact substitution's damaging effect. PMID:33535453 and PMID:21901162 report tumor detection of p.Ala20Val without functional testing. Therefore, no well-established, reproducible, robust functional study supporting a damaging effect is available for this variant, so PS3 is not met at any ACMG/AMP 2015 strength.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • PMID:39202333, Results section 3.2: CTNNB1 c.59C>T (p.Ala20Val) showed a predicted GSK3B recognition-affinity change from log2 0.818 for the reference allele to -0.034 for the alternative allele; this was a computational kinase-motif analysis, not a functional assay.
  • PMID:39202333, Conclusions: the authors state that functional assays are required to validate the impact on the beta-catenin protein.
  • PMID:32365560, Results section 3.1 and Supplementary Table S2: a CTNNB1 p.A13V alteration under the paper's numbering was observed in a medulloblastoma cohort, with no nuclear beta-catenin accumulation by immunohistochemistry; this was not a validated direct assay of the exact c.59C>T substitution.
  • PMID:33535453, Results section 3.5: CTNNB1 c.59C>T (p.Ala20Val) was detected in a Merkel cell carcinoma sample at 9% VAF, without a CTNNB1 functional assay.
  • PMID:21901162, Discussion: CTNNB1 p.A20V was detected in a colorectal tumor and described as potentially not disease-causing; no functional assay was reported.
Still missing
  • A validated, reproducible, robust in vitro or in vivo assay directly testing CTNNB1 p.Ala20Val and demonstrating a damaging effect is not available.
Sources
PM1 ACMG_2015Not met: residue 20 is reported outside critical CTNNB1 sites, and Cancer Hotspots found no statistically significant hotspot. Details ▾Hide ▴
Reasoning

No VCEP covers CTNNB1 and vcep_materials.json has no domain-table entry. The exact residue 20 is not supported as a generic well-established critical domain or mutational hotspot without benign variation: PMID:21901162 explicitly states that p.A20V is outside critical CTNNB1 sites, while PMID:39202333 describes a computationally predicted position at the -3 site of a GSK3B recognition motif but does not establish a validated critical domain. The Cancer Hotspots query returned no statistically significant hotspot. The generic PM1 requirement is therefore not met.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients, PMID:21901162, Discussion: the p.A20V tumor was described as not located in any critical sites and potentially not disease-causing.
  • In Silico Analysis of the Missense Variants of Uncertain Significance of CTNNB1, PMID:39202333, Results section 3.2 and Figure 3a: p.Ala20Val lies at the -3 position of a predicted GSK3B recognition motif and showed a predicted log2 affinity change from 0.818 to -0.034; this is computational evidence, not a validated critical-domain designation.
  • Cancer Hotspots result for CTNNB1 A20: no hotspot row found; the source states that the variant does not lie in a statistically significant hotspot.
Sources
PM5 ACMG_2015Not met: p.Ala20Thr is a same-residue comparator, but the report does not establish it as pathogenic under ACMG/AMP. Details ▾Hide ▴
Reasoning

A different missense change at residue 20, p.Ala20Thr, was reported in a childhood WNT medulloblastoma cohort (PMID:32365560), but the extracted evidence states that it was not a validated pathogenic benchmark and that the cases lacked nuclear beta-catenin accumulation. A different substitution at the same residue is therefore documented, but the required prior determination of pathogenicity is absent. The exact p.Ala20Val finding in PMID:21901162 was described as potentially not disease-causing, further preventing a pathogenic same-residue comparator from being established.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of ..., PMID:32365560, Results section 3.1 and Supplementary Table S2: a different missense change at the same residue, p.A20T, was reported; the extraction characterizes it as same-residue evidence but not a validated pathogenic benchmark.
  • Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients, PMID:21901162, Discussion: p.A20V was described as outside critical sites and potentially not disease-causing.
Sources
PP3 ACMGNot met: REVEL 0.085 is below the >=0.644 PP3 supporting threshold for this missense variant. Details ▾Hide ▴
Reasoning

NM_001904.4:c.59C>T, p.(Ala20Val), is a missense variant, so the generic missense path uses REVEL only; SpliceAI and BayesDel are not used for PP3/BP4 in this situation. The REVEL score is 0.085, below the PP3 supporting threshold of >= 0.644. Therefore PP3 is not met at the ACMG/AMP 2015 supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)...PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: NM_001904.4:c.59C>T produces NP_001895.1:p.(Ala20Val), a missense substitution; the generic missense path therefore uses REVEL only.
  • Local REVEL predictor lookup: score 0.085.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): PP3 supporting threshold is >= 0.644; 0.085 does not reach it.
  • SpliceAI max delta 0.003 and BayesDel -0.403019 were not counted because they are not the named predictor path for a missense variant under the generic rule, and BayesDel has no generic ACMG-strength calibration in this prompt.
Sources
PP5 ACMG_2015Not met: ClinVar shows two ordinary laboratory Uncertain-significance submissions and zero expert-panel classifications for the exact variant. Details ▾Hide ▴
Reasoning

The exact variant is classified as Uncertain significance by two clinical laboratories in ClinVar, with zero expert-panel submissions. The available ClinVar assertions are ordinary laboratory submissions and do not provide an exact-variant expert-panel or other qualifying reputable pathogenic classification; therefore PP5 is not triggered.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 1346762, NM_001904.4(CTNNB1):c.59C>T (p.Ala20Val): Uncertain significance, two clinical laboratories, review status criteria provided, multiple submitters, no conflicts.
  • clinvar_submission_audit.json records expert_panel_submissions = 0 and identifies both exact-match submissions as non-expert clinical-testing submissions.
Sources
BS3 ACMG_2015Not met: no validated in vitro or in vivo assay shows that CTNNB1 p.Ala20Val has no damaging effect on protein function or splicing. Details ▾Hide ▴
Reasoning

The available variant-specific evidence does not meet BS3. No source provides a well-established in vitro or in vivo study showing that CTNNB1 p.Ala20Val has no damaging effect on protein function or splicing. PMID:39202333 contains only computational predictions and states that functional assays are required. PMID:32365560 reports immunohistochemistry for a differently described CTNNB1 alteration and does not establish normal function or normal splicing for p.Ala20Val. PMID:33535453 and PMID:21901162 are tumor sequencing reports without a benign functional assay. The evidence therefore cannot support BS3 at the ACMG/AMP 2015 strong strength.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:39202333, Results section 3.2 and Conclusions: p.Ala20Val was evaluated by computational kinase-motif and stability analyses, and the authors state that functional assays are required; this does not show no damaging effect.
  • PMID:32365560, Results section 3.1 and Supplementary Table S2: the reported p.A13V alteration lacked nuclear beta-catenin accumulation by immunohistochemistry, but this does not establish normal function or normal splicing for CTNNB1 c.59C>T (p.Ala20Val).
  • PMID:33535453, Results section 3.5: the exact variant was detected in a tumor sample, with no benign functional assay reported.
  • PMID:21901162, Discussion: the exact p.A20V variant was reported in a colorectal tumor and may not be disease-causing, but no functional assay established absence of damage.
Still missing
  • A validated, reproducible, robust in vitro or in vivo assay demonstrating no damaging effect on CTNNB1 p.Ala20Val protein function or splicing is not available.
Sources
BP6 ACMG_2015Not met: no qualifying reputable benign report is available; ClinVar contains only two ordinary laboratory Uncertain-significance submissions and no expert-panel submission. Details ▾Hide ▴
Reasoning

The exact variant has no qualifying reputable benign classification in the available evidence. ClinVar contains only two ordinary clinical-laboratory Uncertain-significance submissions and zero expert-panel submissions; ordinary laboratory assertions and aggregate labels cannot trigger BP6.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 1346762 reports Uncertain significance from two clinical laboratories, not Benign or Likely benign.
  • clinvar_submission_audit.json records expert_panel_submissions = 0 for the exact variant.
Sources

Not assessed · 12 · no assessment recorded

PS2 ACMG_2015Not assessed: no report documents confirmed maternity and paternity, a de novo germline event, and absence of family history for this variant. Details ▾Hide ▴
Reasoning

No proband-level germline report documents that CTNNB1 c.59C>T (p.Ala20Val) is de novo, confirms both maternity and paternity, and establishes absence of a family history. The exact-variant papers reviewed describe somatic tumor observations or computational analyses and provide no parental testing or family-history evidence. Therefore, the PS2 requirements cannot be assessed from the available evidence.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • PMID:21901162 reports p.A20V in a colorectal-cancer tumor and matching normal mucosa assessment, but no germline inheritance, parental testing, or family-history data.
  • PMID:39202333 explicitly analyzes c.59C>T (p.Ala20Val) computationally and reports no segregation analysis or germline parental testing.
  • The available exact-variant records do not establish a confirmed de novo germline occurrence with both maternity and paternity confirmed.
Still missing
  • A proband-level germline case report is needed.
  • Maternal and paternal identity/relationships must be confirmed.
  • Parental testing must show the variant is absent in both biological parents.
  • Family history must document no disease history relevant to the criterion.
Sources
PS4 ACMG_2015Not assessed: exact-variant reports provide somatic tumor observations but no affected-versus-control counts or odds ratio with confidence interval. Details ▾Hide ▴
Reasoning

No paper in literature_pass.json packet.ai_classified_papers required verification, and the reviewed exact-variant reports do not provide affected-case and unaffected/population-control counts, a matched-ancestry case frequency comparison, or an odds ratio with a confidence interval. The tumor reports are individual somatic observations and do not establish a germline disease case-control comparison. Therefore the ACMG/AMP PS4 prevalence comparison cannot be assessed from the available evidence.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:21901162 reports one p.A20V colorectal-cancer tumor among 103 tumors but supplies no unaffected-control comparison or odds ratio; the tumor also had several inactivating APC mutations.
  • PMID:33535453 reports the exact c.59C>T (p.Ala20Val) in one Merkel-cell-carcinoma sample at 9% VAF, without a case-control prevalence analysis.
  • PMID:39202333 states that p.Ala20Val was reported in several carcinomas based on secondary database/literature sources, not a variant-specific case-control analysis.
  • literature_pass.json packet.ai_classified_papers is empty; no pre-classified PS4 paper required additional verification.
Still missing
  • A case-control study or equivalent affected-case and matched-control prevalence data for CTNNB1 c.59C>T (p.Ala20Val) are needed.
Sources
PM6 ACMG_2015Not assessed: no proband-level report describes this variant as assumed de novo without confirmed parental testing. Details ▾Hide ▴
Reasoning

No proband-level germline evidence establishes an assumed de novo CTNNB1 c.59C>T (p.Ala20Val) variant without parental confirmation. The exact-variant literature reviewed contains somatic tumor or computational observations and no documented proband phenotype linked to an assumed de novo event. Therefore, PM6 cannot be assessed.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • PMID:21901162 reports the variant in a colorectal tumor and does not report a germline proband, parental testing, or inheritance assessment.
  • PMID:39202333 reports an in-silico analysis of the exact variant and no de novo or parental-testing observation.
  • No available record supplies the minimum proband-level evidence for an assumed de novo event.
Still missing
  • A proband-level germline report is needed.
  • The report must describe an assumed de novo occurrence.
  • The parental-testing limitations and available maternity/paternity information must be documented.
Sources
PP1 ACMG_2015Not assessed: zero documented affected relatives with genotype and phenotype data are available for segregation analysis. Details ▾Hide ▴
Reasoning

No family study reports CTNNB1 c.59C>T (p.Ala20Val) segregating with disease in affected relatives. The exact-variant papers reviewed provide no affected-family-member genotypes, meioses, or phenotype-linked segregation analysis. The available evidence is therefore insufficient to assess PP1 or any stronger segregation level.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Evidence considered
  • PMID:21901162 reports a sporadic colorectal-cancer tumor observation and no family segregation or affected-relative testing.
  • PMID:39202333 reports computational analysis and explicitly provides no segregation analysis.
  • No informative affected-relative meioses or phenotype-genotype cosegregation observations are documented.
Still missing
  • A pedigree with affected relatives is needed.
  • Genotypes for affected relatives must be reported.
  • Clinical phenotypes and disease status for each tested relative must be documented.
  • The number of informative meioses must be available to consider stronger PP1 evidence.
Sources
PP2 ACMG_2015Not assessed: no supplied gene-wide evidence establishes both low benign missense variation and missense as a common CTNNB1 disease mechanism. Details ▾Hide ▴
Reasoning

The available case evidence does not provide a gene-wide benign missense rate or a sufficiently documented disease-mechanism summary establishing both prerequisites of PP2 for CTNNB1. The sources describe individual missense and truncating observations but do not supply the required gene-level quantitative or curated evidence for a low rate of benign missense variation together with missense as a common disease mechanism. PP2 cannot be assessed from the supplied evidence without importing an unstated threshold or external gene-level dataset.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Still missing
  • A validated gene-level assessment of benign missense constraint and the prevalence of missense disease mechanism for CTNNB1 is required.
PP4 ACMG_2015Not assessed: available reports describe somatic tumors, including one with inactivating APC mutations, not a highly specific germline CTNNB1 phenotype. Details ▾Hide ▴
Reasoning

The available exact-variant publications describe somatic colorectal, Merkel-cell, and medulloblastoma tumors rather than a germline CTNNB1-related phenotype or family history. The colorectal report specifically describes coexisting inactivating APC mutations and says the p.A20V change may not be disease-causing, while the other reports do not establish a phenotype highly specific to a single genetic etiology. A germline clinical phenotype sufficiently specific for PP4 is therefore not available.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • PMID:21901162 reports p.A20V in a colorectal tumor with several inactivating APC mutations and states that it may not be disease-causing.
  • PMID:33535453 reports p.(Ala20Val) in one Merkel-cell-carcinoma tumor sample, which is not a specific germline CTNNB1 syndrome phenotype.
  • PMID:32365560 reports an alternative p.A13V notation corresponding to p.A20V in one childhood WNT medulloblastoma case, but does not establish a single-gene germline phenotype for this variant.
Still missing
  • A documented germline patient phenotype or family history highly specific for a single CTNNB1-related disorder is needed.
Sources
BA1 ACMG_2015Not assessed: gnomAD v4.1 total AF is 2.47877e-06, but the required grpmax FAF is unavailable and cannot be replaced by a popmax point estimate. Details ▾Hide ▴
Reasoning

BA1 cannot be adjudicated under the required frequency method because the available gnomAD v2.1 and v4.1 records report grpmax FAF as null. The observed all-comers frequencies are far below 5% (gnomAD v4.1 total AF 2.47877e-06; 4/1,613,702 alleles), but the required filtering allele frequency is unavailable, and the population-specific Finnish point estimate (3.12578e-05; 2/63,984 alleles) must not substitute for grpmax FAF. No pathogenic ClinVar consensus is present; ClinVar reports uncertain significance from two laboratories.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 all-comers record for CTNNB1 NM_001904.4:c.59C>T: total AF 2.4787724127503096e-06, 4/1,613,702 alleles, homozygotes 0; grpmax FAF is null.
  • gnomAD v4.1 reports the highest observed Finnish point estimate as AF 3.125781445361341e-05 from 2/63,984 alleles; this point estimate was not used as a substitute for grpmax FAF.
  • ClinVar variation 1346762 reports uncertain significance from two clinical laboratories with no expert-panel submission.
  • The governing generic calibration supplied for BA1 is >= 0.05, identified as the ACMG/AMP 2015 stand-alone benign allele-frequency threshold (PMID:25741868).
Still missing
  • A reported gnomAD grpmax FAF with its qualifying population allele count is required for BA1 assessment.
Sources
BS1 ACMG_2015Not assessed: gnomAD v4.1 total AF is 2.47877e-06, but grpmax FAF is unavailable and no disorder-specific maximum credible frequency calculation is provided. Details ▾Hide ▴
Reasoning

BS1 cannot be adjudicated under the required frequency method because gnomAD v2.1 and v4.1 report grpmax FAF as null. The all-comers gnomAD v4.1 total AF is only 2.47877e-06, well below the generic 1% default, but that total AF is not the required filtering allele frequency for BS1. The variant is a missense change in CTNNB1, and no disorder-specific maximum credible allele-frequency calculation with prevalence, penetrance, and allelic heterogeneity inputs is available; therefore no BS1 call is made from the default alone.

Rule
Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v4.1 all-comers record for CTNNB1 NM_001904.4:c.59C>T: total AF 2.4787724127503096e-06, 4/1,613,702 alleles; grpmax FAF is null.
  • The Finnish population has a point estimate of 3.125781445361341e-05 from 2/63,984 alleles, but this popmax point estimate was not used for BS1.
  • The generic BS1 default supplied for this case is >= 0.01; Whiffin et al. 2017 (PMID:28518168) was identified in the governing instructions as the source for maximum credible allele-frequency reasoning, but the required disease-specific inputs are not available.
Still missing
  • A reported grpmax FAF and a disorder-specific maximum credible allele-frequency calculation are required for BS1 assessment.
Sources
BS2 ACMG_2015Not assessed: gnomAD reports zero homozygotes but does not document a specific healthy adult carrier with genotype, age, and phenotype. Details ▾Hide ▴
Reasoning

BS2 is not assessable from the available population records. gnomAD v4.1 reports 4 total alleles and zero homozygotes, while gnomAD v2.1 reports 4 total alleles and zero homozygotes; these records do not document an identified healthy adult carrier, genotype, age, or phenotype. The apparently healthy nature of gnomAD participants is insufficient by itself to establish the required healthy-adult observation for this criterion.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v2.1 reports 4/282,536 total alleles and zero homozygotes for the variant.
  • gnomAD v4.1 reports 4/1,613,702 total alleles and zero homozygotes for the variant.
  • The available gnomAD records provide population-level allele and homozygote counts, not an individual-level healthy-adult phenotype observation.
Still missing
  • A documented healthy adult individual carrying the variant in the genotype required by the disorder's inheritance model is needed.
Sources
BS4 ACMG_2015Not assessed: no affected relatives have documented genotype and phenotype results showing that the variant fails to segregate. Details ▾Hide ▴
Reasoning

No affected family members carrying or lacking CTNNB1 c.59C>T (p.Ala20Val) are described, so there is no documented non-segregation observation. The available exact-variant papers do not provide a familial pedigree, affected-relative testing, or phenotype assessments that could establish lack of segregation. BS4 is therefore not assessed.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • PMID:21901162 contains no familial segregation or affected-relative non-segregation data.
  • PMID:39202333 contains no family genotype-phenotype analysis.
  • No affected-member testing result is available to establish lack of segregation.
Still missing
  • A familial pedigree with affected individuals is needed.
  • Variant testing and disease-status assessment for affected relatives are needed.
  • Phenocopy and multiple-pathogenic-variant considerations must be evaluated if non-segregation is observed.
Sources
BP1 ACMG_2015Not assessed: supplied extracts show both truncating and missense CTNNB1 disease observations but do not establish that disease is primarily truncating. Details ▾Hide ▴
Reasoning

The supplied evidence does not include a source-registry-cited gene-wide review establishing that CTNNB1 disease is caused primarily by truncating variants. Individual sources document both truncating and missense CTNNB1 disease-associated observations, but the available extracts do not provide a complete disease-variant spectrum or a defensible proportion for the word primarily. BP1 therefore remains not assessed rather than being inferred from selected reports.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Still missing
  • A source-registry-cited gene-level disease spectrum demonstrating that CTNNB1 disease is primarily caused by truncating variants is required.
BP2 ACMG_2015Not assessed: no germline paired pathogenic variant or phase result is reported, so neither the BP2 trans nor cis condition can be evaluated. Details ▾Hide ▴
Reasoning

No report in the available evidence documents this variant in trans with a pathogenic variant in a fully penetrant dominant disorder or in cis with a pathogenic variant. The exact-variant literature consists of somatic tumor observations and does not provide germline paired-variant testing or phase, so BP2 cannot be assessed.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • Li et al. 2011, PMID:21901162: the p.A20V observation was in a colorectal-cancer tumor; no germline paired pathogenic variant, inheritance, or phase data were reported.
  • PMID:33535453: the exact variant was observed in a Merkel cell carcinoma tumor sample at 9% VAF; no germline cis/trans information was reported.
Still missing
  • Germline testing of the relevant individual and/or parents or offspring to identify a pathogenic paired variant and establish cis/trans phase.
Sources
Not applicable · 5· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_001904.4:c.59C>T in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Ala20Val). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM3 N/ANot applicable: CTNNB1-related disease is autosomal dominant in this case, whereas PM3 is restricted to recessive disorders with a pathogenic variant confirmed in trans. Details ▾Hide ▴
Reasoning

PM3 is not applicable because the case evidence identifies the CTNNB1-related disorder context as autosomal dominant rather than recessive. The available exact-variant reports are somatic tumor observations and provide no germline affected-proband, pathogenic-partner, or parent-tested trans-phase observation; therefore PM3 cannot be applied to this dominant disorder.

Rule
For recessive disorders, detected in trans with a pathogenic variant...This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • The case evidence identifies CTNNB1-related neurodevelopmental disorder as autosomal dominant.
  • Li et al. 2011, PMID:21901162: CTNNB1 p.A20V was reported in a colorectal-cancer tumor; matching mucosa was assessed for somatic versus germline status, but no germline inheritance, parent testing, or phase was reported.
  • PMID:33535453: CTNNB1 c.59C>T (p.Ala20Val) was detected in a Merkel cell carcinoma tumor sample at 9% VAF; this is somatic tumor evidence, not a germline trans observation.
Sources
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_001904.4:c.59C>T in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Ala20Val). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_001904.4:c.59C>T in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Ala20Val). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001904.4:c.59C>T in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Ala20Val). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
CTNNB1
Transcript
NM_001904.4
Coding (HGVS c.)
NM_001904.4:c.59C>T
Protein (HGVS p.)
NP_001895.1:p.(Ala20Val)
GRCh38
chr3:41224571 C>T
GRCh37
chr3:41266062 C>T
Location and type
Exon 3 · missense
ClinVar
1346762
COSMIC
COSV62708242

Gene diagram

Every interpreted variant in CTNNB1, mapped onto the exon structure of NM_001904.4. Select a row to find it on the plot.

CTNNB1NM_001904.4
Fetching transcript structure from UCSC…
gnomAD v4.1 4 / 1,613,702 alleles AF 2.48e-06 · 0 homozygotes
gnomAD v2.1 4 / 282,536 alleles AF 1.42e-05 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 2.5e-06 · 4 / 1,613,702 alleles · 0 hom
European (Finnish)2 / 63,984 3.1e-05
Admixed American1 / 59,892 1.7e-05
South Asian1 / 91,080 1.1e-05
0 alternate alleles recorded in 7 other groups: Remaining individuals, Amish, East Asian, Middle Eastern, Ashkenazi Jewish, African/African American, European (non-Finnish).

gnomAD v2.1

AF 1.4e-05 · 4 / 282,536 alleles · 0 hom
European (Finnish)2 / 25,112 8e-05
African/African American1 / 24,966 4e-05
Admixed American1 / 35,290 2.8e-05
0 alternate alleles recorded in 5 other groups: Ashkenazi Jewish, East Asian, European (non-Finnish), Remaining individuals, South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.47877e-06; MAF= 0.00025%, 4/1613702 alleles, homozygotes = 0) and has highest observed frequency in the European (Finnish) population (AF= 3.12578e-05; MAF= 0.00313%, 2/63984 alleles, homozygotes = 0).

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.41575e-05; MAF= 0.00142%, 4/282536 alleles, homozygotes = 0) and has highest observed frequency in the European (Finnish) population (AF= 7.96432e-05; MAF= 0.00796%, 2/25112 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -45 bp
0.000
SpliceAI acceptor gainat -381 bp
0.002
SpliceAI donor lossat +83 bp
0.000
SpliceAI donor gainat -250 bp
0.003
Pangolin splice lossmagnitude shown
-0.001
Pangolin splice gain
0.008

Other predictors

REVEL
0.085
BayesDel
-0.403

How the predictions were used

BP4 SupportingACMGMet, supporting: REVEL 0.085 is below the <=0.29 BP4 threshold for this missense variant. Details ▾Hide ▴
Reasoning

NM_001904.4:c.59C>T, p.(Ala20Val), is a missense variant, so the generic missense path uses REVEL only; SpliceAI and BayesDel are not used for PP3/BP4 in this situation. The REVEL score is 0.085, at or below the BP4 supporting threshold of <= 0.29. Therefore BP4 is met at the ACMG/AMP 2015 supporting strength.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)...BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: NM_001904.4:c.59C>T produces NP_001895.1:p.(Ala20Val), a missense substitution; the generic missense path therefore uses REVEL only.
  • Local REVEL predictor lookup: score 0.085.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): BP4 supporting threshold is <= 0.29; 0.085 meets it.
  • SpliceAI max delta 0.003 and BayesDel -0.403019 were not counted because they are not the named predictor path for a missense variant under the generic rule, and the same prediction must not be double-counted across PP3/BP4/BP7.
Sources
PP3 ACMGNot met: REVEL 0.085 is below the >=0.644 PP3 supporting threshold for this missense variant. Details ▾Hide ▴
Reasoning

NM_001904.4:c.59C>T, p.(Ala20Val), is a missense variant, so the generic missense path uses REVEL only; SpliceAI and BayesDel are not used for PP3/BP4 in this situation. The REVEL score is 0.085, below the PP3 supporting threshold of >= 0.644. Therefore PP3 is not met at the ACMG/AMP 2015 supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)...PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: NM_001904.4:c.59C>T produces NP_001895.1:p.(Ala20Val), a missense substitution; the generic missense path therefore uses REVEL only.
  • Local REVEL predictor lookup: score 0.085.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): PP3 supporting threshold is >= 0.644; 0.085 does not reach it.
  • SpliceAI max delta 0.003 and BayesDel -0.403019 were not counted because they are not the named predictor path for a missense variant under the generic rule, and BayesDel has no generic ACMG-strength calibration in this prompt.
Sources
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001904.4:c.59C>T in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Ala20Val). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.085. BayesDel score = -0.403019.

1 paper record listed. 1 cited in the classification. None of the listed paper records explicitly indicates that the variant is named.

Cited in the classification

  • Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients.
    The paper explicitly reports CTNNB1 p.A20V in one colorectal-cancer tumor and states that it is outside critical CTNNB1 sites and may not be disease-causing; the tumor also had several inactivating APC mutations.
    → BP5 · supporting Names this variant
    PMID 21901162 ↗
    Source detail
    The other CRC had the p.A20V mutation, which is not located in any of the critical sites, does not change amino acid polarity and may not be disease-causing. This tumour had several inactivating APC mutations.

    Location Discussion, paragraph beginning ‘CRCs with intact APC may carry mutations in CTNNB1’

    Context CTNNB1 exon 3 was analyzed by PCR with high-resolution melting screening and bidirectional sequencing in 103 colorectal tumors from 102 Czech CRC patients, with corresponding mucosa assessed for somatic versus germline status.

Other recorded publications

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    Richards S et al. · 2015
    No paper-specific finding is recorded.
    PMID 25741868 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.47877e-06; MAF= 0.00025%, 4/1613702 alleles, homozygotes = 0) and has highest observed frequency in the European (Finnish) population (AF= 3.12578e-05; MAF= 0.00313%, 2/63984 alleles, homozygotes = 0).

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.41575e-05; MAF= 0.00142%, 4/282536 alleles, homozygotes = 0) and has highest observed frequency in the European (Finnish) population (AF= 7.96432e-05; MAF= 0.00796%, 2/25112 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (2 clinical laboratories). (ClinVarID = 1346762)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.085. BayesDel score = -0.403019.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. CTNNB1 (β-catenin), a transcriptional activator, is recurrently mutated in various cancers including endometrial and hepatocellular cancers.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV62708242, n = 8 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.